Literature DB >> 17545007

Induction therapy in cardiac transplantation: when and why?

David A Baran1.   

Abstract

Induction therapy has continued to be a subject of controversy in heart transplantation for more than 20 years. It is an example of a therapy that is logical, and ought to be better than "doing without." However, a careful review of the evidence suggests otherwise. Except for patients where the benefits clearly outweigh the short and long-term risks, the use of induction therapy should be avoided. In immunosuppression, as in life, there is no "free lunch." Clinicians need to be certain they fully understand what they are ordering when asking for induction therapy to be administered to their patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545007     DOI: 10.1016/j.hfc.2007.02.009

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  2 in total

Review 1.  New directions in immunosuppression after heart transplantation.

Authors:  David A Baran
Journal:  Nat Rev Cardiol       Date:  2013-04-30       Impact factor: 32.419

2.  Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis.

Authors:  Soulef Guendouz; Philippe Grimbert; Costin Radu; Daniel Cherqui; Chady Salloum; Nicolas Mongardon; Sami Maghrebi; Karim Belhadj; Fabien Le Bras; Emmanuel Teiger; Jean-Paul Couetil; Adriana Balan; Mounira Kharoubi; Mélanie Bézard; Silvia Oghina; Diane Bodez; Luc Hittinger; Vincent Audard; Violaine Planté-Bordeneuve; Alexandre De la Taille; Eric Bergoend; Valerie Frenkel; Pascale Fanen; Vincent Leroy; Christophe Duvoux; Maryvonnick Carmagnat; Thierry Folliguet; Thibaud Damy
Journal:  Transplant Direct       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.